A Gap Between Willingness and Uptake: Findings From Mixed Methods Research on HIV Prevention Among Black and Latina Transgender Women

Tonia Poteat, Andrea Wirtz, Mannat Malik, Erin Cooney, Christopher Cannon, W David Hardy, Renata Arrington-Sanders, Maren Lujan, Thespina Yamanis, Tonia Poteat, Andrea Wirtz, Mannat Malik, Erin Cooney, Christopher Cannon, W David Hardy, Renata Arrington-Sanders, Maren Lujan, Thespina Yamanis

Abstract

Background: Black and Latina transgender women (BLTW) face significant HIV disparities with estimated HIV prevalence up to 50% and annual incidence rates as high as 2.8 per 100 person-years. However, few studies have evaluated the acceptability and uptake of high-impact HIV prevention interventions among BLTW.

Setting: Data collection took place in Baltimore, MD and Washington, DC from May 2015 to May 2017.

Methods: This mixed methods study included quantitative interviewer-administered surveys, key informant interviews, and focus group discussions. Rapid HIV testing followed each survey. Logistic regression models tested associations between legal gender affirmation (ie, desired name and gender marker on identity documents), transgender pride, history of exchange sex, HIV risk perception, and willingness to take pre-exposure prophylaxis (PrEP). Transcripts of qualitative data were coded to identify common themes related to engagement in HIV prevention.

Results: Among 201 BLTW, 56% tested HIV-positive and 87% had heard of PrEP. Only 18% who had heard of PrEP had ever taken it. Of the 72 self-reported HIV-negative or status-unknown BLTW who had never taken PrEP, 75% were willing to take it. In multivariable analyses, history of exchange sex was associated with willingness to take PrEP, whereas greater HIV knowledge and transgender pride were associated with lower likelihood of willingness to take PrEP. Concern about drug interactions with hormone therapy was the most frequently reported barrier to PrEP uptake.

Conclusions: Noting the disconnect between PrEP willingness and uptake among BLTW, HIV prevention programs could bridge this gap by responding to identified access barriers and incorporating community-derived strategies.

Figures

Figure 1.
Figure 1.
Reasons for PrEP Unwillingness and Experiences while on PrEP *n=17: HIV-negative BLTW who have never taken PrEP and reported unwillingness to take PrEP if it were available to them **n=26: BLTW who reported ever taking PrEP

References

    1. Nuttbrock L, Bockting W, Rosenblum A, et al. Gender abuse, depressive symptoms, and HIV and other sexually transmitted infections among male-to-female transgender persons: a three-year prospective study. American journal of public health. 2013;103(2):300–307.
    1. Salazar LF, Crosby RA, Jones J, Kota K, Hill B, Masyn KE. Contextual, experiential, and behavioral risk factors associated with HIV status: a descriptive analysis of transgender women residing in Atlanta, Georgia. International journal of STD & AIDS. 2017;0(0):1–8.
    1. Habarta N, Wang G, Mulatu MS, Larish N. HIV Testing by Transgender Status at Centers for Disease Control and Prevention-Funded Sites in the United States, Puerto Rico, and US Virgin Islands, 2009–2011. American journal of public health. 2015;105(9):1917–1925.
    1. Reisner SL, Jadwin-Cakmak L, White Hughto JM, Martinez M, Salomon L, Harper GW. Characterizing the HIV Prevention and Care Continua in a Sample of Transgender Youth in the U.S. AIDS and behavior. 2017;21(12):3312–3327.
    1. Poteat T, Malik M, Scheim A, Elliott A. HIV Prevention Among Transgender Populations: Knowledge Gaps and Evidence for Action. Current HIV/AIDS reports. 2017;14(4):141–152.
    1. Grant RM, Lama JR, Anderson PL, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. New England Journal of Medicine. 2010;363(27):2587–2599.
    1. Murnane PM, Celum C, Mugo N, et al. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS (London, England). 2013;27(13):2155–2160.
    1. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. 2013;381(9883):2083–2090.
    1. Van Damme L, Corneli A, Ahmed K, et al. Preexposure Prophylaxis for HIV Infection among African Women. New England Journal of Medicine. 2012;367(5):411–422.
    1. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. New England Journal of Medicine. 2015;372(6):509–518.
    1. Deutsch MB, Glidden DV, Sevelius J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015;2(12):e512–519.
    1. Huang YA, Zhu W, Smith DK, Harris N, Hoover KW. HIV Preexposure Prophylaxis, by Race and Ethnicity - United States, 2014–2016. MMWR Morbidity and mortality weekly report. 2018;67(41):1147–1150.
    1. van Epps P, Maier M, Lund B, et al. Medication Adherence in a Nationwide Cohort of Veterans Initiating Pre-exposure Prophylaxis (PrEP) to Prevent HIV Infection. Journal of acquired immune deficiency syndromes (1999). 2018;77(3):272–278.
    1. Nunn AS, Brinkley-Rubinstein L, Oldenburg CE, et al. Defining the HIV pre-exposure prophylaxis care continuum. AIDS (London, England). 2017;31(5):731–734.
    1. Calabrese SK. Interpreting Gaps Along the Preexposure Prophylaxis Cascade and Addressing Vulnerabilities to Stigma. American journal of public health. 2018;108(10):1284–1286.
    1. Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From Efficacy to Effectiveness: Facilitators and Barriers to PrEP Acceptability and Motivations for Adherence Among MSM and Transgender Women in New York City. AIDS patient care and STDs. 2013;27(4):248–254.
    1. Eaton LA, Kalichman SC, Price D, Finneran S, Allen A, Maksut J. Stigma and Conspiracy Beliefs Related to Pre-exposure Prophylaxis (PrEP) and Interest in Using PrEP Among Black and White Men and Transgender Women Who Have Sex with Men. AIDS and behavior. 2017;21(5):1236–1246.
    1. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. The Lancet Infectious diseases. 2014;14(9):820–829.
    1. Poteat T, German D, Flynn C. The conflation of gender and sex: Gaps and opportunities in HIV data among transgender women and MSM. Global public health. 2016;11(7–8):835–848.
    1. Garnett M, Hirsch-Moverman Y, Franks J, Hayes-Larson E, El-Sadr WM, Mannheimer S Limited awareness of pre-exposure prophylaxis among black men who have sex with men and transgender women in New York city. AIDS care. 2018;30(1):9–17.
    1. Jalil EM, Grinsztejn B, Velasque L, et al. Awareness, Willingness, and PrEP Eligibility Among Transgender Women in Rio de Janeiro, Brazil. Journal of acquired immune deficiency syndromes (1999) 2018;79(4):445–452.
    1. Oldenburg CE, Le B, Toan T, et al. HIV Pre-exposure Prophylaxis Indication and Readiness Among HIV-Uninfected Transgender Women in Ho Chi Minh City, Vietnam. AIDS and behavior. 2016;20(Suppl 3):365–370.
    1. Wang Z, Lau JTF, Yang X, et al. Acceptability of Daily Use of Free Oral Pre-exposure Prophylaxis (PrEP) Among Transgender Women Sex Workers in Shenyang,China. AIDS and behavior. 2017;21(12):3287–3298.
    1. Zalazar V, Aristegui I, Kerr T, et al. High Willingness to Use HIV Pre-Exposure Prophylaxis Among Transgender Women in Argentina. Transgender health. 2016;1(1):266–273.
    1. Restar AJ, Kuhns L, Reisner SL, Ogunbajo A, Garofalo R, Mimiaga MJ. Acceptability of Antiretroviral Pre-exposure Prophylaxis from a Cohort of Sexually Experienced Young Transgender Women in Two U.S Cities. AIDS and behavior. 2018.
    1. Rael CT, Martinez M, Giguere R, et al. Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City. AIDS and behavior. 2018;22(11):3627–3636.
    1. Kuhns LM, Reisner SL, Mimiaga MJ, Gayles T, Shelendich M, Garofalo R. Correlates of PrEP Indication in a Multi-Site Cohort of Young HIV-Uninfected Transgender Women. AIDS and behavior. 2016;20(7):1470–1477.
    1. Sevelius JM, Keatley J, Calma N, Arnold E. ‘I am not a man’: Trans-specific barriers and facilitators to PrEP acceptability among transgender women. Global public health. 2016;11(7–8):1060–1075.
    1. Larkin PM, Begley CM, Devane D. Breaking from binaries - using a sequential mixed methods design. Nurse researcher. 2014;21(4):8–12.
    1. Yamanis T, Malik M, Del Rio-Gonzalez AM, et al. Legal Immigration Status is Associated with Depressive Symptoms among Latina Transgender Women in Washington,DC. International journal of environmental research and public health. 2018;15(6).
    1. 2017. Poverty Guidelines. .
    1. Testa RJ, Habarth J, Peta J, Balsam K, Bockting W. Development of the Gender Minority Stress and Resilience Measure. Psychology of Sexual Orientation and Gender Diversity. 2015;2(1):65.
    1. Fay H, Baral SD, Trapence G, et al. Stigma, Health Care Access, and HIV Knowledge Among Men Who Have Sex With Men in Malawi, Namibia, and Botswana. AIDS and behavior. 2011;15(6):1088–1097.
    1. Auerbach JD, Kinsky S, Brown G, Charles V. Knowledge, Attitudes, and Likelihood of Pre-Exposure Prophylaxis (PrEP) Use Among US Women at Risk of Acquiring HIV. AIDS patient care and STDs. 2014;29(2):102–110.
    1. Eaton LA, Matthews DD, Driffin DD, Bukowski L, Wilson PA, Stall RD. A Multi-US City Assessment of Awareness and Uptake of Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Black Men and Transgender Women Who Have Sex with Men. Prevention science : the official journal of the Society for Prevention Research. 2017;18(5):505–516.
    1. Hoagland B, De Boni RB, Moreira RI, et al. Awareness and Willingness to Use Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men and Transgender Women in Brazil. AIDS and behavior. 2017;21(5):1278–1287.
    1. Grinsztejn B, Hoagland B, Moreira RI, et al. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. Lancet HIV. 2018;5(3):e136–e145.
    1. Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: Implications for conducting a qualitative descriptive study. Nursing & Health Sciences. 2013;15(3):398–405.
    1. Mehrotra ML, Rivet Amico K, McMahan V, et al. The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men. AIDS and behavior. 2018.
    1. Braun HM, Candelario J, Hanlon CL, et al. Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns. LGBT health. 2017;4(5):371–375.
    1. Hiransuthikul A, Himmad K, Kerr S, et al. Drug-drug interactions between the use of feminizing hormone therapy and pre-exposure prophylaxis among transgender women: The iFACT study. Paper presented at: AIDS 2018; Amsterdam, The Netherlands.
    1. Shieh E, Marzinke M, Fuchs E, et al. Transgender Women on Estrogen Have Significantly Lower Tenofovir/Emtricitabine Concentrations During Directly Observed Dosing When Compared to Cis Men. Paper presented at: HIV Research for Prevention2018; Madrid, Spain.
    1. Reyniers T, Nostlinger C, Laga M, et al. Choosing Between Daily and Event-Driven Pre-exposure Prophylaxis: Results of a Belgian PrEP Demonstration Project. Journal of acquired immune deficiency syndromes (1999). 2018;79(2):186–194.
    1. Bekker LG, Roux S, Sebastien E, et al. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial. Lancet HIV. 2018;5(2):e68–e78.
    1. Poteat T, Wirtz AL, Radix A, et al. HIV risk and preventive interventions in transgender women sex workers. Lancet (London, England). 2015;385(9964):274–286.
    1. Project PRIDE. .
    1. DC Health: DC PrEP Drug Assistance Program. .
    1. Perez-Brumer A, Nunn A, Hsiang E, et al. “We don’t treat your kind”: Assessing HIV health needs holistically among transgender people in Jackson, Mississippi. PloS one. 2018;13(11):e0202389.
    1. James SE, Herman JL, Rankin S, Keisling M, Mottet L, Anafi M. The Report of the 2015 U.S. Transgender Survey Washington, DC: National Center for Transgender Equality; 2016.
    1. Marks SJ, Merchant RC, Clark MA, et al. Potential Healthcare Insurance and Provider Barriers to Pre-Exposure Prophylaxis Utilization Among Young Men Who Have Sex with Men. AIDS patient care and STDs. 2017;31(11):470–478.
    1. Sevelius JM, Reznick OG, Hart SL, Schwarcz S. Informing interventions: the importance of contextual factors in the prediction of sexual risk behaviors among transgender women. AIDS education and prevention : official publication of the International Society for AIDS Education. 2009;21(2):113–127.
    1. Sevelius JM. Gender Affirmation: A Framework for Conceptualizing Risk Behavior among Transgender Women of Color. Sex roles. 2013;68(11–12):675–689.
    1. Fletcher JB, Kisler KA, Reback CJ. Housing status and HIV risk behaviors among transgender women in Los Angeles. Arch Sex Behav. 2014;43(8):1651–1661.
    1. De Santis JP, Patsdaughter CA. The dangerous intersection of violence and HIV infection. J Assoc Nurses AIDS Care. 2014;25(1 Suppl):S1–4.
    1. Raiford JL, Hall GJ, Taylor RD, Bimbi DS, Parsons JT. The Role of Structural Barriers in Risky Sexual Behavior, Victimization and Readiness to Change HIV/STI-Related Risk Behavior Among Transgender Women. AIDS and behavior. 2016;20(10):2212–2221.
    1. Raiford JL, Hall GJ, Taylor RD, Bimbi DS, Parsons JT. Erratum to: The Role of Structural Barriers in Risky Sexual Behavior, Victimization and Readiness to Change HIV/STI-Related Risk Behavior Among Transgender Women. AIDS and behavior. 2017;21(7):2215–2215.
    1. Wirtz AL, Poteat TC, Malik M, Glass N. Gender-Based Violence Against Transgender People in the United States: A Call for Research and Programming. Trauma, violence & abuse. 2018:1524838018757749.
    1. Jewkes RK, Dunkle K, Nduna M, Shai N. Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: a cohort study. The Lancet. 2010;376(9734):41–48.
    1. Pronyk PM, Hargreaves JR, Kim JC, et al. Effect of a structural intervention for the prevention of intimate-partner violence and HIV in rural South Africa: a cluster randomised trial. 2006;368(9551):1973–1983.
    1. Roberts ST, Haberer J, Celum C, et al. Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study. Journal of acquired immune deficiency syndromes (1999) 2016;73(3):313–322.
    1. Braksmajer A, Leblanc NM, El-Bassel N, Urban MA, McMahon JM. Feasibility and acceptability of pre-exposure prophylaxis use among women in violent relationships. AIDS care. 2018:1–6.
    1. Gilbert L, Raj A, Hien D, Stockman J, Terlikbayeva A, Wyatt G. Targeting the SAVA (Substance Abuse, Violence, and AIDS) Syndemic Among Women and Girls: A Global Review of Epidemiology and Integrated Interventions. Journal of acquired immune deficiency syndromes (1999). 2015;69 Suppl 2:S118–127.
    1. Collier KL, Colarossi LG, Hazel DS, Watson K, Wyatt GE. Healing Our Women for Transgender Women: Adaptation, Acceptability, and Pilot Testing. AIDS education and prevention : official publication of the International Society for AIDS Education. 2015;27(5):418–431.
    1. Reisner SL, Perez-Brumer AG, McLean SA, et al. Perceived Barriers and Facilitators to Integrating HIV Prevention and Treatment with Cross-Sex Hormone Therapy for Transgender Women in Lima, Peru. AIDS Behav. 2017.
    1. Hood JE, Eljallad T, Abad J, et al. Getting pre-exposure prophylaxis to high-risk transgender women: lessons from Detroit, USA. Sexual health. 2018;15(6):562–569.
    1. Melendez RM, Pinto RM. HIV prevention and primary care for transgender women in a community-based clinic. J Assoc Nurses AIDS Care. 2009;20(5):387–397.
    1. Reback CJ, Ferlito D, Kisler KA, Fletcher JB. Recruiting, Linking, and Retaining High-risk Transgender Women into HIV Prevention and Care Services: An Overview of Barriers, Strategies, and Lessons Learned. The international journal of transgenderism. 2015;16(4):209–221.
    1. Andrasik MP, Yoon R, Mooney J, et al. Exploring barriers and facilitators to participation of male-to-female transgender persons in preventive HIV vaccine clinical trials. Prevention science : the official journal of the Society for Prevention Research. 2014;15(3):268–276.
    1. Calabrese SK, Earnshaw VA, Underhill K, Hansen NB, Dovidio JF. The impact of patient race on clinical decisions related to prescribing HIV pre-exposure prophylaxis (PrEP): assumptions about sexual risk compensation and implications for access. AIDS and behavior. 2014;18(2):226–240.
    1. Calabrese SK, Tekeste M, Mayer KH, et al. Considering Stigma in the Provision of HIV Pre-Exposure Prophylaxis: Reflections from Current Prescribers. AIDS patient care and STDs. 2019;33(2):79–88.
    1. Blackstock OJ, Moore BA, Berkenblit GV, et al. A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians. Journal of general internal medicine. 2017;32(1):62–70.
    1. Calabrese SK, Magnus M, Mayer KH, et al. Putting PrEP into Practice: Lessons Learned from Early-Adopting U.S. Providers’ Firsthand Experiences Providing HIV Pre-Exposure Prophylaxis and Associated Care. PloS one. 2016;11(6):e0157324.
    1. Calabrese SK, Earnshaw VA, Underhill K, et al. Prevention paradox: Medical students are less inclined to prescribe HIV pre-exposure prophylaxis for patients in highest need. Journal of the International AIDS Society. 2018;21(6):e25147.
    1. Meyers K, Golub SA. Planning ahead for implementation of long-acting HIV prevention: challenges and opportunities. Current opinion in HIV and AIDS. 2015;10(4):290–295.
    1. Schwartz J, Grimm J. PrEP on Twitter: Information, Barriers, and Stigma. Health communication. 2017;32(4):509–516.
    1. Sevelius JM, Deutsch MB, Grant R. The future of PrEP among transgender women: the critical role of gender affirmation in research and clinical practices. Journal of the International AIDS Society. 2016;19(7(Suppl 6)):21105.
    1. Wolf RC, Adams D, Dayton R, et al. Putting the t in tools: a roadmap for implementation of new global and regional transgender guidance. J Int AIDS Soc. 2016;19(3 Suppl 2):20801.
    1. Perez-Brumer AG, Reisner SL, McLean SA, et al. Leveraging social capital: multilevel stigma, associated HIV vulnerabilities, and social resilience strategies among transgender women in Lima, Peru. Journal of the International AIDS Society. 2017;20(1):21462.
    1. World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations–2016 update. World Health Organization; 2016.
    1. Poteat T, Keatley J. Transgender People and HIV: Policy Brief. Geneva, Switzerland: World Health Organization; 2015.
    1. Sevelius J, Murray LR, Martinez Fernandes N, Veras MA, Grinsztejn B, Lippman SA. Optimising HIV programming for transgender women in Brazil. Culture, health & sexuality. 2019;21(5):543–558.
    1. Reisner SL, Bradford J, Hopwood R, et al. Comprehensive transgender healthcare: the gender affirming clinical and public health model of Fenway Health. Journal of urban health : bulletin of the New York Academy of Medicine. 2015;92(3):584–592.
    1. CliniQ. 2019; . Accessed 15 May 2019.
    1. Educación. ACISy. Gender-Affirmative Transgender Care to Improve the HIV Treatment Cascade. 2018; . Accessed 15 May 2019.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe